Sucampo Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SCMP and buy or sell other stocks, ETFs, and their options commission-free!

About SCMP

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. 

CEO
Peter S. Greenleaf, MBA
CEOPeter S. Greenleaf, MBA
Employees
Employees
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
1996
Founded1996
Employees
Employees

SCMP Key Statistics

Market cap
835.37M
Market cap835.37M
Price-Earnings ratio
-5.47
Price-Earnings ratio-5.47
Dividend yield
Dividend yield
Average volume
1.46M
Average volume1.46M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$18.75
52 Week high$18.75
52 Week low
$9.30
52 Week low$9.30

Stock Snapshot

As of today, Sucampo Pharmaceuticals(SCMP) shares are valued at $18.00. The company's market cap stands at 835.37M, with a P/E ratio of -5.47.

During the trading day, Sucampo Pharmaceuticals(SCMP) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.46M.

Over the past 52 weeks, Sucampo Pharmaceuticals(SCMP) stock has traded between a high of $18.75 and a low of $9.30.

Over the past 52 weeks, Sucampo Pharmaceuticals(SCMP) stock has traded between a high of $18.75 and a low of $9.30.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.